news bytes
LUPIN AND ELI LILLY EXPAND PARTNERSHIP IN INDIA
Pharma Major Lupin Limited( Lupin) and Eli Lilly and Company( India) on December 01, 2016 announced an expansion of their partnership in India with the launch of Eglucent ®, a new brand of Lilly’ s rapid-acting insulin analog Lispro.
According to the agreement, Lupin will market and sell Eglucent ® through its own specialty field force while Lilly will be responsible for manufacturing and import. Lilly will continue to sell Lispro under the brand name Humalog ® through its existing channels. Lupin had earlier collaborated with Lilly( July, 2011) to promote and distribute Lilly’ s Huminsulin range of products in India and Nepal.
Eglucent ® is indicated for the treatment of patients with diabetes mellitus. It is an injectable medication designed to improve blood sugar control in patients with type 1 and 2 diabetes. Eglucent ® will be available in the Indian market in both, the cartridge and disposable pen form. Eglucent ® is a prescription drug that should be taken only when prescribed by a registered physician. It is intended as an adjunct to diet and exercise to improve the glycemic control.
“ We have been very pleased with our partnership with Lupin and are happy to see it grow with the launch of Eglucent ®. The intent of this launch, which is the first for Lilly in the entire Emerging Markets region, is to increase the reach of analog insulin Lispro ® to more patients and healthcare professionals. We believe this is a big step in our journey to help fight the rising disease burden in India.” said Edgard Olaizola, Managing Director, Lilly India.
STRIDES SHASUN TO ACQUIRE PERRIGO’ S US FDA APPROVED API FACILITY IN INDIA
Strides Shasun Limited has announced the signing of definitive agreements to acquire the entire shareholding in Perrigo API India Private Limited( Perrigo API India) for INR 1000 Million. The transaction is subject to customary closing conditions and expected to be closed by December 31, 2016.
The Company already has a portfolio of integrated products under development and with the R & D teams for formulations and API working on a joint development platform, the Company is confident of reaching its stated filling run rate of 20-25 molecules which will largely comprise of integrated molecules.
Perrigo API India’ s facility brings into the fold a US FDA approved API facility located at Ambernath, Maharashtra, to be used for captive consumption and will augment the Company’ s resources to handle high velocity of new product development and commercial launches in the formulations portfolio. The facility with a potential capacity of 600 tons per year had zero 483s during its last US FDA inspection.
Commenting on the development, Shashank Sinha, Group CEO of Strides Shasun stated“ With this acquisition, we bring into
our fold a manufacturing facility designed to handle multipurpose small batch productions and accelerates our time to market. This augurs well for the Strides’ stated strategy of building a backward integrated portfolio of niche and small volume products for the regulated markets.”
DR KIRAN SHAW TO DEBUT AT SERENDIPITY ARTS FESTIVAL 2016
Biocon’ s Chairperson and Managing Director Kiran Mazumdar- Shaw is enabling the showcase of a special exhibition of Science Gallery Bengaluru,‘ Entanglement: A Dance between Art & Science’ at the Serendipity Arts Festival in Goa this December. Conceptualized and produced by the Centre for Experimental Media and Arts( CEMA) at Srishti Institute of Art Design and Technology along with Science Gallery Dublin,‘ Entanglement’ will comprise a series of spectacles, experiments and projects on the fleeting boundaries of art-science-technology-culture- and philosophy.
This is the first edition of the Serendipity Arts Festival, a multidisciplinary arts event set over a period of eight days from December 16th to 23rd in Panaji, Goa. The festival will be curated by a panel of experts spanning all the major disciplines including the performing arts, visual arts, and culinary arts.
The‘ Entanglement’ exemplifies the connect between art and science and is an initiative by Science Gallery, Bengaluru, a partner of Science Gallery, Dublin under the auspices of Science Gallery International. The exhibition is jointly funded by Biocon Foundation, Biocon’ s CSR Wing and the Department of IT, BT & Science and Technology, Government of Karnataka.
‘ Entanglement’ will illustrate ones interaction and understanding of the natural and physical world. Through form, experience, and interaction, a collective of international and Indian artists, scientists, coders, and hackers will engage the public through projects on Environment, Gaming, Artificial Intelligence and Interactivity, and Physical Computing and Data Quantification.
Commenting on her association with the‘ Entanglement’, Dr Kiran Mazumdar-Shaw said,“ Through this unique Science Gallery Bengaluru showcase, I want to project the mélange of the art and the science. While these two disciplines are seemingly distinct, they together embody significant creative expression. Serendipity Arts Festival is the ideal platform to showcase‘ Entanglement: Dance between Art & Science’ since this festival aims to break the notion of art as an isolated silo and creates space for interdisciplinary exploration of art across disciplines.”
ICMR INVITES LETTER OF CLAIM OVER THERAPEUTIC USE OF STEM CELLS
Stem cell research is a very fast growing field. The scientific community has witnessed major development in the field from autologous to allogeneic mesenchymal to embryonic and now induced pluripotent stem cells. ICMR has been regularly receiving claims on possible therapeutic solutions for varied disease conditions using stem cell.
Taking into consideration this situation and to understand position of India in global scenario, the Director General, ICMR invites‘ Letter of Claim’ on therapeutic use of stem cells from all
42
BioVoiceNews | December 2016- January 2017